1
|
Watt KI, Henstridge DC, Ziemann M, Sim CB, Montgomery MK, Samocha-Bonet D, Parker BL, Dodd GT, Bond ST, Salmi TM, Lee RS, Thomson RE, Hagg A, Davey JR, Qian H, Koopman R, El-Osta A, Greenfield JR, Watt MJ, Febbraio MA, Drew BG, Cox AG, Porrello ER, Harvey KF, Gregorevic P. Yap regulates skeletal muscle fatty acid oxidation and adiposity in metabolic disease. Nat Commun 2021; 12:2887. [PMID: 34001905 PMCID: PMC8129430 DOI: 10.1038/s41467-021-23240-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Accepted: 04/13/2021] [Indexed: 02/07/2023] Open
Abstract
Obesity is a major risk factor underlying the development of metabolic disease and a growing public health concern globally. Strategies to promote skeletal muscle metabolism can be effective to limit the progression of metabolic disease. Here, we demonstrate that the levels of the Hippo pathway transcriptional co-activator YAP are decreased in muscle biopsies from obese, insulin-resistant humans and mice. Targeted disruption of Yap in adult skeletal muscle resulted in incomplete oxidation of fatty acids and lipotoxicity. Integrated 'omics analysis from isolated adult muscle nuclei revealed that Yap regulates a transcriptional profile associated with metabolic substrate utilisation. In line with these findings, increasing Yap abundance in the striated muscle of obese (db/db) mice enhanced energy expenditure and attenuated adiposity. Our results demonstrate a vital role for Yap as a mediator of skeletal muscle metabolism. Strategies to enhance Yap activity in skeletal muscle warrant consideration as part of comprehensive approaches to treat metabolic disease.
Collapse
Affiliation(s)
- K I Watt
- Centre for Muscle Research, The University of Melbourne, Melbourne, VIC, Australia
- Dept of Physiology, The University of Melbourne, Melbourne, VIC, Australia
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Dept of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia
| | - D C Henstridge
- School of Health Sciences, University of Tasmania, Hobart, Tas, Australia
| | - M Ziemann
- Deakin University, Melbourne, VIC, Australia
| | - C B Sim
- Murdoch Children's Research Institute, Melbourne, VIC, Australia
| | - M K Montgomery
- Dept of Physiology, The University of Melbourne, Melbourne, VIC, Australia
| | - D Samocha-Bonet
- Division of Healthy Aging, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - B L Parker
- Centre for Muscle Research, The University of Melbourne, Melbourne, VIC, Australia
- Dept of Physiology, The University of Melbourne, Melbourne, VIC, Australia
| | - G T Dodd
- Dept of Physiology, The University of Melbourne, Melbourne, VIC, Australia
| | - S T Bond
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - T M Salmi
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Dept of Biochemistry and Molecular Biology, The University of Melbourne, Melbourne, VIC, Australia
- Sir Peter MacCallum Dept of Oncology, The University of Melbourne, Melbourne, VIC, Australia
| | - R S Lee
- Metabolic Disease and Obesity Phenotyping Facility, Monash University, Melbourne, VIC, Australia
| | - R E Thomson
- Centre for Muscle Research, The University of Melbourne, Melbourne, VIC, Australia
| | - A Hagg
- Centre for Muscle Research, The University of Melbourne, Melbourne, VIC, Australia
| | - J R Davey
- Centre for Muscle Research, The University of Melbourne, Melbourne, VIC, Australia
| | - H Qian
- Centre for Muscle Research, The University of Melbourne, Melbourne, VIC, Australia
| | - R Koopman
- Centre for Muscle Research, The University of Melbourne, Melbourne, VIC, Australia
| | - A El-Osta
- Dept of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia
- Dept of Pathology, The University of Melbourne, Melbourne, VIC, Australia
- Hong Kong Institute of Diabetes and Obesity, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
| | - J R Greenfield
- Division of Healthy Aging, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
- Dept of Diabetes and Endocrinology, St Vincent's Hospital, Darlinghurst, NSW, Australia
| | - M J Watt
- Dept of Physiology, The University of Melbourne, Melbourne, VIC, Australia
| | - M A Febbraio
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia
| | - B G Drew
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - A G Cox
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Dept of Biochemistry and Molecular Biology, The University of Melbourne, Melbourne, VIC, Australia
- Sir Peter MacCallum Dept of Oncology, The University of Melbourne, Melbourne, VIC, Australia
| | - E R Porrello
- Dept of Physiology, The University of Melbourne, Melbourne, VIC, Australia
- Murdoch Children's Research Institute, Melbourne, VIC, Australia
| | - K F Harvey
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Sir Peter MacCallum Dept of Oncology, The University of Melbourne, Melbourne, VIC, Australia
- Dept of Anatomy and Developmental Biology, and Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia
| | - P Gregorevic
- Centre for Muscle Research, The University of Melbourne, Melbourne, VIC, Australia.
- Dept of Physiology, The University of Melbourne, Melbourne, VIC, Australia.
- Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
- Dept of Neurology, The University of Washington School of Medicine, Seattle, WA, USA.
| |
Collapse
|
3
|
Chan SW, Lim CJ, Huang C, Chong YF, Gunaratne HJ, Hogue KA, Blackstock WP, Harvey KF, Hong W. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene 2010; 30:600-10. [PMID: 20972459 PMCID: PMC3033532 DOI: 10.1038/onc.2010.438] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The transcriptional co-activators YAP and TAZ are downstream targets inhibited by the Hippo tumor suppressor pathway. YAP and TAZ both possess WW domains, which are important protein–protein interaction modules that mediate interaction with proline-rich motifs, most commonly PPXY. The WW domains of YAP have complex regulatory roles as exemplified by recent reports showing that they can positively or negatively influence YAP activity in a cell and context-specific manner. In this study, we show that the WW domain of TAZ is important for it to transform both MCF10A and NIH3T3 cells and to activate transcription of ITGB2 but not CTGF, as introducing point mutations into the WW domain of TAZ (WWm) abolished its transforming and transcription-promoting ability. Using a proteomic approach, we discovered potential regulatory proteins that interact with TAZ WW domain and identified Wbp2. The interaction of Wbp2 with TAZ is dependent on the WW domain of TAZ and the PPXY-containing C-terminal region of Wbp2. Knockdown of endogenous Wbp2 suppresses, whereas overexpression of Wbp2 enhances, TAZ-driven transformation. Forced interaction of WWm with Wbp2 by direct C-terminal fusion of full-length Wbp2 or its TAZ-interacting C-terminal domain restored the transforming and transcription-promoting ability of TAZ. These results suggest that the WW domain-mediated interaction with Wbp2 promotes the transforming ability of TAZ.
Collapse
Affiliation(s)
- S W Chan
- Cancer and Developmental Cell Biology Division, Institute of Molecular and Cell Biology, Singapore
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Dinudom A, Harvey KF, Komwatana P, Jolliffe CN, Young JA, Kumar S, Cook DI. Roles of the C termini of alpha -, beta -, and gamma -subunits of epithelial Na+ channels (ENaC) in regulating ENaC and mediating its inhibition by cytosolic Na+. J Biol Chem 2001; 276:13744-9. [PMID: 11278874 DOI: 10.1074/jbc.m011273200] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The amiloride-sensitive epithelial Na(+) channels (ENaC) in the intralobular duct cells of mouse mandibular glands are inhibited by the ubiquitin-protein ligase, Nedd4, which is activated by increased intracellular Na(+). In this study we have used whole-cell patch clamp methods in mouse mandibular duct cells to investigate the role of the C termini of the alpha-, beta-, and gamma-subunits of ENaC in mediating this inhibition. We found that peptides corresponding to the C termini of the beta- and gamma-subunits, but not the alpha-subunit, inhibited the activity of the Na(+) channels. This mechanism did not involve Nedd4 and probably resulted from the exogenous C termini interfering competitively with the protein-protein interactions that keep the channels active. In the case of the C terminus of mouse beta-ENaC, the interacting motif included betaSer(631), betaAsp(632), and betaSer(633). In the C terminus of mouse gamma-ENaC, it included gammaSer(640). Once these motifs were deleted, we were able to use the C termini of beta- and gamma-ENaC to prevent Nedd4-mediated down-regulation of Na(+) channel activity. The C terminus of the alpha-subunit, on the contrary, did not prevent Nedd4-mediated inhibition of the Na(+) channels. We conclude that mouse Nedd4 interacts with the beta- and gamma-subunits of ENaC.
Collapse
Affiliation(s)
- A Dinudom
- Department of Physiology, University of Sydney, New South Wales 2006, Australia
| | | | | | | | | | | | | |
Collapse
|
11
|
Harvey KF, Harvey NL, Michael JM, Parasivam G, Waterhouse N, Alnemri ES, Watters D, Kumar S. Caspase-mediated cleavage of the ubiquitin-protein ligase Nedd4 during apoptosis. J Biol Chem 1998; 273:13524-30. [PMID: 9593687 DOI: 10.1074/jbc.273.22.13524] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The onset of apoptosis is coupled to the proteolytic activation of a family of cysteine proteases, termed caspases. These proteases cleave their target proteins after an aspartate residue. Following caspase activation during apoptosis, a number of specific proteins have been shown to be cleaved. Here we show that Nedd4, a ubiquitin-protein ligase containing multiple WW domains and a calcium/lipid-binding domain, is also cleaved during apoptosis induced by a variety of stimuli including Fas-ligation, gamma-radiation, tumor necrosis factor-alpha, C-8 ceramide, and etoposide treatment. Extracts from apoptotic cells also generated cleavage patterns similar to that seen in vivo, and this cleavage was inhibited by an inhibitor of caspase-3-like proteases. In vitro, Nedd4 was cleaved by a number of caspases, including caspase-1, -3, -6, and -7. By site-directed mutagenesis, one of the in vitro caspase cleavage sites in mouse Nedd4 was mapped to a DQPD237 downward arrow sequence, which is conserved between mouse, rat, and human proteins. This is the first report demonstrating that an enzyme of the ubiquitin pathway is cleaved by caspases during apoptosis.
Collapse
Affiliation(s)
- K F Harvey
- Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Frome Road, Adelaide, SA 5000, Australia
| | | | | | | | | | | | | | | |
Collapse
|